Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.6%

157 terminated/withdrawn out of 1156 trials

Success Rate

80.7%

-5.8% vs industry average

Late-Stage Pipeline

2%

25 trials in Phase 3/4

Results Transparency

65%

428 of 657 completed trials have results

Key Signals

138 recruiting428 with results121 terminated36 withdrawn

Enrollment Performance

Analytics

Phase 2
457(43.1%)
N/A
308(29.0%)
Phase 1
255(24.0%)
Phase 3
21(2.0%)
Early Phase 1
16(1.5%)
Phase 4
4(0.4%)
1061Total
Phase 2(457)
N/A(308)
Phase 1(255)
Phase 3(21)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1156)

Showing 20 of 1156 trials
NCT03689595Enrolling By Invitation

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Role: lead

NCT01659203Phase 1Recruiting

Proton or Photon RT for Retroperitoneal Sarcomas

Role: collaborator

NCT04290546Phase 1Completed

CIML NK Cell in Head & Neck Cancer

Role: lead

NCT06239220Phase 2Recruiting

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Role: lead

NCT07735442Not ApplicableNot Yet Recruiting

BRIDGE-SIC Efficacy Trial

Role: lead

NCT07735624Phase 2Not Yet Recruiting

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Role: lead

NCT00400946Phase 3Completed

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Role: lead

NCT05765500Phase 2Recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Role: lead

NCT00458536Phase 1Completed

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Role: collaborator

NCT07517666Not ApplicableEnrolling By Invitation

Genetic Information for Families After Tumor Testing Study

Role: collaborator

NCT05327465Not ApplicableRecruiting

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Role: lead

NCT04323774Not ApplicableActive Not Recruiting

Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes

Role: lead

NCT01574274Phase 2Active Not Recruiting

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

Role: lead

NCT02912572Phase 2Active Not Recruiting

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Role: lead

NCT07732140Not ApplicableNot Yet Recruiting

Listen Aphasia Pilot Study

Role: lead

NCT02675959Phase 2Recruiting

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Role: collaborator

NCT03417739Phase 2Terminated

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Role: lead

NCT04045470Not ApplicableRecruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Role: lead

NCT07729150Not ApplicableNot Yet Recruiting

Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

Role: lead

NCT02876302Phase 2Completed

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Role: lead